Ranbaxy Laboratories, India's top drugmaker by sales, reported a consolidated net loss of Rs 586 crore as foreign exchange losses ballooned despite a surge in sales.
Ranbaxy, controlled by Japan's Daiichi Sankyo Co , recorded a loss of Rs 599 crore on foreign currency derivatives in fiscal second quarter ended June, compared to a gain of Rs 112 crore a year earlier, it said.
Net sales rose 54.5 percent to Rs 3,174 crore Ranbaxy said.
Analysts had forecast net profit at Rs 321 crore on net sales of Rs 2,906 crore according to Thomson Reuters
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app